Abstract P6-10-01: Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-34)
CF Singer(Innsbruck Medical University), G Michael(Innsbruck Medical University), Christoph Tinchon(LKH Hochsteiermark), AL Petzer(Innsbruck Medical University), P Dubsky, A Pichler(Innsbruck Medical University), Rupert Bartsch(Universitätszahnklinik Wien), Daniel Egle(Innsbruck Medical University), Sophie Frantal(Statistics Austria), V. Wette(Innsbruck Medical University), M-KM Tea(Innsbruck Medical University), R. Greil(Paracelsus Medical University), Georg Pfeiler(Medical University of Vienna), Edgar Petru(Medical University of Graz), Michael Hubalek(Innsbruck Medical University), P. Sevelda, Herbert Stoeger(Medical University of Graz), M. Balic(Innsbruck Medical University), M. Rudas(Comprehensive Cancer Center Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna)
Cited by 2
Related Papers
Inferring expressed genes by whole-genome sequencing of plasma DNA
|Nature Genetics|2016|463
Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice
|Science|2018|422
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
|Annals of Oncology|2013|403
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
|Nature Medicine|2022|395
Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure–activity relationship
|Biochemical Pharmacology|2005|303